Levchenko Tatyana S, Hartner William C, Torchilin Vladimir P
The Center for Pharmaceutical Biotechnology & Nanomedicine, Department of Pharmaceutical Sciences, Northeastern University, Mugar Building, Room 312, 360 Huntington Avenue, Boston, MA 02115, USA.
Ther Deliv. 2012 Apr;3(4):501-14. doi: 10.4155/tde.12.18.
Liposome-based pharmaceuticals used within the cardiovascular system are reviewed in this article. The delivery of diagnostic and therapeutic agents by plain liposomes and liposomes with surface-attached targeting antibodies or polyethylene glycol to prolong their circulation time and accumulation at vascular injuries, ischemic zones or sites of thrombi are also discussed. An overview of the advantages and disadvantages of liposome-mediated in vitro, ex vivo and in vivo targeting is presented, including discussion of the targeting of liposomes to pathological sites on the blood vessel wall and a description of liposomes that can be internalized by endothelial cells. Diagnostic liposomes used to target myocardial infarction and the relative importance of liposome size, targetability of immunoliposomes and prolonged circulation time on the efficiency of sealing hypoxia-induced plasma membrane damage to cardiocytes are discussed as a promising approach for therapy. The progress in the use of targeted liposomal plasmids for the transfection of hypoxic cardiomyocytes and myocardium is presented. Stent-mediated liposomal-based drug delivery is also reviewed briefly.
本文综述了用于心血管系统的基于脂质体的药物。还讨论了普通脂质体以及带有表面附着靶向抗体或聚乙二醇的脂质体递送诊断和治疗剂，以延长其循环时间并在血管损伤、缺血区域或血栓部位蓄积。概述了脂质体介导的体外、离体和体内靶向的优缺点，包括讨论脂质体靶向血管壁病理部位以及可被内皮细胞内化的脂质体的描述。作为一种有前景的治疗方法，讨论了用于靶向心肌梗死的诊断脂质体以及脂质体大小、免疫脂质体靶向性和延长循环时间对封闭缺氧诱导的心肌细胞膜损伤效率的相对重要性。介绍了使用靶向脂质体质粒转染缺氧心肌细胞和心肌的进展。还简要综述了支架介导的基于脂质体的药物递送。
